证券代码：002737 证券简称：葵花药业 公告编号：2025-064 葵花药业集团股份有限公司 第五届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 二、董事会会议审议情况 1、审议通过《关于公司 2025 年第三季度报告的议案》 表决结果：同意 9 票，反对 0 票，弃权 0 票，通过。 专门委员会审议情况:本议案提交董事会审议前业经公司第五届董事会审计 委员会 2025 年第四次会议审议通过。 三、备查文件: 1、公司第五届董事会第十二次会议决议 2、公司第五届董事会审计委员会 2025 年第四次会议决议 特此公告。 葵花药业集团股份有限公司 董 事 会 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第五届董事 会第十二次会议于 2025 年 10 月 27 日上午 9 时以通讯方式召开。会议由公司董 事长关玉秀女士召集，会议通知及议案于 2025 年 10 月 22 日通过电子邮件形式 发出。会议应参加表决董事 9 人，实际参加表决董事 9 人。本次会议召集、召开 程序符合《公司法》及相关法 ...

Core Insights - The company reported a revenue of 374 million yuan for the third quarter, representing a year-on-year decline of 14.90% [1] - The net profit for the third quarter was a loss of 115 million yuan, a decrease of 214.27% compared to the previous year [1] - For the first three quarters, the total revenue was 1.684 billion yuan, down 43.24% year-on-year [1] - The net profit for the first three quarters showed a loss of 33.54 million yuan, reflecting a decline of 105.72% [1]

Revenue and Profitability - The company's revenue for Q3 2025 was ¥373,840,721.51, representing a decrease of 14.90% compared to the same period last year, and a year-to-date revenue of ¥1,683,984,047.39, down 43.24% year-on-year[5] - The net profit attributable to shareholders was -¥114,848,599.10 for the quarter, a decline of 214.27%, and a year-to-date net profit of -¥33,538,693.69, down 105.72%[5] - The basic and diluted earnings per share were both -¥0.20, reflecting a decrease of 217.65% compared to the same period last year[5] - The company experienced a substantial reduction in net profit for the quarter, which was -¥45,914,346.86, a decrease of 107.58% compared to the same period last year[10] - Total operating revenue for the current period was ¥1,683,984,047.39, a decrease of 43.3% compared to ¥2,966,906,461.88 in the previous period[17] - Net profit for the current period was a loss of ¥45,914,346.86, compared to a profit of ¥605,513,521.75 in the previous period, representing a significant decline[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,123,453,375.74, a decrease of 12.06% from the end of the previous year[5] - The company’s total equity attributable to shareholders decreased by 7.46% to ¥4,052,632,698.81 compared to the end of the previous year[5] - The company’s total current assets decreased from 3,885,593,091.44 yuan to 3,261,322,981.89 yuan, a decline of approximately 16%[13] - Total current liabilities decreased from 1,027,526,250.87 yuan to 720,514,381.01 yuan, a decline of approximately 30%[14] - The total liabilities decreased to ¥891,554,090.46 from ¥1,235,876,758.46, reflecting a reduction of 28%[15] Cash Flow and Investments - The cash flow from operating activities for the year-to-date was ¥220,323,992.20, an increase of 155.20% compared to the same period last year[10] - The net cash flow from operating activities was ¥220,323,992.20, a recovery from a negative cash flow of ¥399,173,131.02 in the previous period[20] - Cash inflows from operating activities totaled ¥1,686,942,207.77, down 35.4% from ¥2,610,224,347.59 in the previous period[20] - Investment cash inflows were significantly higher at ¥8,119,116,312.91 compared to ¥3,400,000,000.00 in the previous period, indicating a strong investment recovery[20] - Net cash flow from investment activities was -276,914,999.75, compared to 254,800,846.26 in the previous period, indicating a decline in investment performance[21] - Total cash inflow from financing activities was 18,000,000.00, while cash outflow was 314,007,935.81, resulting in a net cash flow from financing activities of -296,007,935.81[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 52,430[11] - The largest shareholder, KuaHua Group Co., Ltd., holds 45.41% of shares, totaling 265,200,000 shares[11] Operational Efficiency - The company reported a significant decrease in sales expenses, which amounted to ¥336,479,049.08, down 37.70% year-on-year, attributed to reduced sales and enhanced cost control[9] - The investment income increased by 53.89% to ¥19,675,919.34, primarily due to higher returns from financial products[9] - The company reported a significant reduction in employee compensation liabilities from 165,286,636.67 yuan to 67,586,943.36 yuan, a decrease of about 59%[14] Financial Reporting and Standards - The company did not undergo an audit for the third quarter financial report, which may affect investor confidence[22] - The company plans to implement new accounting standards starting in 2025, which may impact future financial reporting[22]

Core Insights - On October 22, Kewang Pharmaceutical's stock rose by 1.17%, with a trading volume of 798.94 million yuan [1] - As of September 30, the number of shareholders decreased by 2.06% to 52,400, while the average circulating shares per person increased by 2.10% to 11,145 shares [2] Financing and Margin Trading - On October 22, Kewang Pharmaceutical had a financing buy amount of 6.15 million yuan and a financing repayment of 13.38 million yuan, resulting in a net financing buy of -7.24 million yuan [1] - The total margin trading balance as of October 22 was 157 million yuan, with the financing balance at 155 million yuan, accounting for 1.70% of the circulating market value, which is below the 10th percentile level over the past year [1] - The company had a short selling repayment of 800 shares and a short selling amount of 900 shares on October 22, with a short selling balance of 127.93 million yuan, also below the 10th percentile level over the past year [1] Financial Performance - For the first half of 2025, Kewang Pharmaceutical reported a revenue of 1.31 billion yuan, a year-on-year decrease of 48.17%, and a net profit attributable to shareholders of 81.31 million yuan, down 83.28% year-on-year [2] - Cumulatively, the company has distributed 4.045 billion yuan in dividends since its A-share listing, with 1.752 billion yuan distributed over the past three years [3] Shareholder Structure - As of June 30, 2025, the top ten circulating shareholders included E Fund CSI Dividend ETF, which held 3.1612 million shares, a decrease of 436,800 shares from the previous period [3] - Hong Kong Central Clearing Limited entered as a new shareholder, holding 2.9699 million shares, while Southern CSI 1000 ETF also entered as a new shareholder with 2.6960 million shares [3]

Core Viewpoint - The announcement indicates that the company has received approval from the National Medical Products Administration for clinical trials of a pediatric medication aimed at treating acute bronchitis in children [1] Group 1 - The company is a fully-owned subsidiary of Kew Flower Pharmaceutical Group Co., Ltd. [1] - The approved product is a cough syrup specifically designed for children, named "Pediatric Lung Heat Cough and Wheezing Oral Solution" [1] - The clinical trial will focus on the treatment of acute bronchitis in children [1]

Group 1 - Dingjide's subsidiary has successfully launched the industrial production of POE materials, achieving stable production of qualified products [1] - Xinhua Insurance reported a 19% year-on-year increase in original insurance premium income for the first three quarters, totaling 172.705 billion yuan [1] - Chunfeng Power achieved a 30.89% year-on-year increase in net profit for the first three quarters, with total revenue reaching 14.15 billion yuan [1][2] Group 2 - Guangsheng Nonferrous expects a net profit of 100 million to 130 million yuan for the first three quarters, marking a turnaround from losses [1] - Aobi Zhongguang anticipates a net profit of approximately 108 million yuan for the first three quarters, with revenue growth of 103.5% [1] - Guobang Pharmaceutical reported a 15.78% year-on-year increase in net profit for the first three quarters, totaling 6.7 billion yuan [1] Group 3 - Zhujiang Co. manages 428 projects with a signed construction area of approximately 50.9853 million square meters as of September 2025 [1] - Kecuan Technology has terminated its application for issuing convertible bonds, considering its development plan and actual situation [1] - Guoxin Securities has received approval to register 15 billion yuan in short-term corporate bonds [1] Group 4 - Aihua Pharmaceutical's clinical trial for a pediatric cough syrup has been approved by the National Medical Products Administration [1] - Xinjiang Jiaojian signed new construction contracts worth 1.413 billion yuan in the third quarter [1] - Sichuan Shuangma's subsidiary has received approval for the listing of a raw material drug used in treating various diseases [1] Group 5 - Gansu Energy's 1,000 MW coal-fired unit has officially commenced commercial operation [1] - Zhejiang Energy reported a 4.68% year-on-year increase in power generation for the first three quarters, totaling 135.234 billion kWh [1] - Tiandi Source's contract sales amount for the first nine months decreased by 16.18% to 3.085 billion yuan [1] Group 6 - Biological Shares' subsidiary has obtained a new veterinary drug registration certificate for a vaccine [1] - Jintong Co. reported a 4.03% year-on-year increase in net profit for the first three quarters, totaling 2.283 billion yuan [1] - Rihua Technology plans to invest 800 million yuan in a new project for industrial ray detection equipment [1] Group 7 - Zhongtian Technology has won multiple marine project bids totaling approximately 1.788 billion yuan [1] - Qingsong Co. has completed the disposal of a 148-acre industrial park project, transferring it for 163 million yuan [1] - Tongyuan Petroleum has successfully bid for a $126 million oil and gas service project in Algeria [1] Group 8 - Hengmingda's chairman proposed a share buyback plan of 200 million to 400 million yuan [1] - Deyi Cultural plans to reduce its holdings by up to 1% of the company's shares [1] - Feirongda's major shareholder plans to reduce its holdings by up to 2.36% of the company's shares [1] Group 9 - Mankun Technology plans to issue convertible bonds to raise no more than 760 million yuan for high-end PCB production and digital upgrades [1] - Sanlian Forging's shareholder plans to reduce its holdings by up to 3% of the company's shares [1] - Huagong Technology intends to jointly establish a venture capital fund with a target size of 500 million yuan [1] Group 10 - Shida Shenghua expects a net loss of 49 million to 75 million yuan for the first three quarters [1] - Huichuangda's major shareholder plans to reduce its holdings by up to 0.65% of the company's shares [1] - Yuxin Electronics reported a 60.21% year-on-year increase in net profit for the first three quarters, totaling 73.3941 million yuan [1] Group 11 - Yiwei Communication expects a 50% to 55% decline in net profit for the first three quarters [1] - Lio Co. plans to reduce its repurchased shares by up to 135 million shares [1] - Sichuan Shuangma's subsidiary has received approval for a new drug registration [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of a pediatric medication aimed at treating acute bronchitis in children [1] Company Summary - The company,葵花药业, announced that its wholly-owned subsidiary, 黑龙江葵花药业股份有限公司, has obtained a clinical trial approval notice for its pediatric medication, 小儿肺热咳喘口服液 [1]

Core Viewpoint - Kuaihua Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its pediatric medication, indicating a strategic move to expand its product offerings in the pediatric market [1] Company Summary - Kuaihua Pharmaceutical's wholly-owned subsidiary, Heilongjiang Kuaihua Pharmaceutical Co., Ltd., has been granted a clinical trial approval for its pediatric lung heat cough syrup, aimed at treating acute bronchitis in children [1] - As of the latest report, Kuaihua Pharmaceutical's market capitalization stands at 9.1 billion yuan [1] Industry Summary - In the first half of 2025, the pharmaceutical sector accounted for 99.61% of Kuaihua Pharmaceutical's total revenue, highlighting the company's strong focus on the pharmaceutical industry [1] - Other business segments contributed only 0.39% to the overall revenue, indicating a concentrated business model [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its pediatric medication, indicating a strategic expansion into treating acute bronchitis in children [1] Company Summary - The company’s wholly-owned subsidiary, Heilongjiang Kewang Pharmaceutical Co., Ltd., has been granted a clinical trial approval notice for its product, Pediatric Lung Heat Cough and Wheezing Oral Solution [1] - The clinical trial will focus on the use of this medication for treating acute bronchitis in children, building on its existing indications [1] Industry Summary - The approval reflects ongoing regulatory support for pediatric medications, which may enhance market opportunities for companies in the pharmaceutical sector [1]

证券代码：002737 证券简称：葵花药业 公告编号：2025-063 受理号：CXZL2500062 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 8 月 4 日受理的小儿肺热咳喘口服液临床试验申请符合药品注册的有关要求， 在进一步完善临床试验方案的基础上，同意本品开展用于儿童急性支气管炎的临 床试验。 二、药品研发及相关情况 小儿肺热咳喘口服液（以下简称"小儿肺热"）为公司持有的已上市品种， 本次申请进行的临床试验是在小儿肺热原功能主治的基础上开展用于"儿童急性 支气管炎"的相关研究。 三、风险提示 葵花药业集团股份有限公司 关于获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）全资子公司 黑龙江葵花药业股份有限公司于近日收到国家药品监督管理局（以下简称"国家 药监局"）核准签发的关于小儿肺热咳喘口服液的《药物临床试验批准通知书》， 同意本品开展用于儿童急性支气管炎的临床试验。现将有关情况公告如下： 一、药品基本情况 药物名称：小儿肺热咳喘 ...